News | Coronavirus (COVID-19) | April 27, 2023

Ultromics Granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis Detection

The platform uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis 

The platform, EchoGo Amyloidosis, uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart.

Ultromics' EchoGo Amyloidosis receives FDA Breakthrough Device Designation 


April 27, 2023 — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis. 

The platform, EchoGo Amyloidosis, uses artificial intelligence to analyze echocardiograms and detect the presence of cardiac amyloidosis, a condition caused by deposits of abnormal proteins in the heart tissue, using only a single commonly acquired ultrasound view of the heart. 

The novel technology is designed to address the unmet need for earlier diagnosis of amyloidosis patients, which otherwise may go unnoticed until the disease has advanced, delaying treatment, and adversely impacting patient outcomes. 

Cardiac amyloidosis is a heterogeneous disease that can be difficult to diagnose, often requiring specialized expertise and testing. The disease is subclassified based on the specific protein involved, with the major subtypes being transthyretin amyloidosis (ATTR cardiac amyloidosis), caused by misfolding of the transthyretin protein, and a rarer form called light chain amyloidosis (AL cardiac amyloidosis), caused by accumulation of immunoglobulin light chains. 

"Receiving a breakthrough designation for EchoGo Amyloidosis, emphasizes the importance of this innovation," said Dr Ross Upton, CEO and Founder of Ultromics. "This is our second breakthrough designation and brings us one step closer to achieving our goal of providing earlier and more accurate diagnosis for this debilitating, underdiagnosed disease. We are excited to continue working with our partners to bring this technology to market and help improve outcomes for patients." 

FDA Breakthrough Device Designation recognizes novel innovations that demonstrate the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases. This is an important milestone for the field of healthcare overall, and more saliently, a giant leap forward for amyloidosis patients which suffer a dismal 5-year mortality of 44%-65% after diagnosis, if not caught early enough. 

The product, intended as a module within Ultromics' EchoGo Platform, has been developed with data from several leading clinical collaborators and with support from Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. The company is preparing regulatory submissions for the U.S., and the device could be approved for commercialization as soon as early 2024. 

"While treatments exist to help slow or halt the progression of cardiac Amyloidosis, underdiagnosis in the early stages of disease is a huge challenge," said Najat Khan, Ph.D., Chief Data Science Officer and Global Head, Strategy & Operations at Janssen Research & Development, LLC. "When applied to routine tests like echocardiograms, artificial intelligence is demonstrating exciting potential to help facilitate earlier disease detection – with the goal of connecting patients with treatment sooner and, ultimately, driving better health outcomes." 

Ultromics' Amyloidosis platform is the company's second technology to receive FDA Breakthrough Device Designation within the last year. Its HFpEF device, EchoGo Heart Failure received Breakthrough Device Designation in 2022 and Marketing Authorization in 2023. EchoGo Amyloidosis is currently in development with the algorithm as a candidate for FDA medical device submission. 

For more information: www.ultromics.com 


Related Content

Feature | Cardiac Imaging | By Mohammad Sahebjalal, MD

Invented in 1896 by Enrico Salvioni, the fluoroscope remains a flagship technology of modern medicine. The live video X ...

Home May 04, 2023
Home
News | Cardiac Imaging

April 26, 2023 — In the majority of cases, graft failure after heart transplantation is attributable to abnormalities ...

Home April 26, 2023
Home
News | Cardiac Imaging

April 14, 2023 — Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S ...

Home April 14, 2023
Home
News | Cardiac Imaging

February 8, 2023 — Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the ...

Home February 08, 2023
Home
Videos | Cardiac Imaging

Artificial intelligence and general consolidation were two top cardiology trends at RSNA22. ITN/DAIC spoke with Val ...

Home January 23, 2023
Home
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Home January 13, 2023
Home
News | Cardiac Imaging

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10 ...

Home November 29, 2022
Home
News | Cardiac Imaging

November 28, 2022 – UltraSight, an Israeli-based digital health pioneer transforming cardiac imaging through the power ...

Home November 28, 2022
Home
News | Cardiac Imaging

November 28, 2022 — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare ...

Home November 28, 2022
Home
Feature | Cardiac Imaging

Discover the key features of cardiovascular structured reporting that drive adoption, including automated data flow, EHR ...

Home November 07, 2022
Home
Subscribe Now